Anzeige
Erschienen in:
08.08.2023
Does GLP-RA Plus an SGLT2 Inhibitor Yield Greater Weight Loss in Patients with Obesity and Diabetes than Monotherapy?
Erschienen in: Current Cardiovascular Risk Reports | Ausgabe 9/2023
Einloggen, um Zugang zu erhaltenAbstract
Purpose of Review
With the rate of obesity increasing in the USA, effective and safe medications for weight loss are more important than ever in patient care. Glucagon-like peptide 1 receptor agonists (GLP-RA) and sodium-glucose co-transporter 2 (SGLT2) inhibitors are two medication for type 2 diabetes that have shown benefit in randomized control trials for not just diabetes but weight loss and lowering cardiovascular and renal risks. These novel medications have continued to show benefits in weight loss in randomized control trials. A literature review was conducted to determine the impact of GLP-RAs and SGLT2 inhibitors as combination therapy for weight loss in patients with diabetes. Another purpose of this review was to define a specific patient population that would potentially benefit from both a GLP-RA and SGLT2 for weight loss.
Recent Findings
Several monotherapy trials for GLP-RA and SGLT2 inhibitors have shown positive weight loss reductions along with hemoglobin A1c reductions (HbA1c) and other metabolic parameters. Several studies of combination therapy with a GLP-RA plus an SGLT2 inhibitor have shown greater weight loss than just monotherapy with either agent.
Summary
There are many promising studies that show significant weight loss from monotherapy and combination therapy in patients with type 2 diabetes. Further randomized control trials are needed to identify which patients would benefit most from combination therapy.
